Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. has announced a pilot program at the Royal Papworth Hospital NHS Foundation Trust to integrate its Steriwave nasal photodisinfection therapy into cardiac surgical care pathways. This initiative aims to enhance patient safety and surgical outcomes by reducing surgical site infections, particularly in the context of rising antimicrobial resistance. The pilot positions Royal Papworth among a growing list of cardiac centers adopting pre-surgical nasal photodisinfection protocols, with previous implementations showing significant reductions in infections. The Steriwave technology offers a rapid, non-antibiotic solution that does not induce resistance, making it a valuable tool in infection prevention strategies.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary photodisinfection technology in various stages of development. Ondine’s Steriwave photodisinfection system is approved for nasal decolonization in several countries and is undergoing clinical trials in the US for regulatory approval.
Average Trading Volume: 377,558
Technical Sentiment Signal: Buy
Current Market Cap: £75.16M
See more insights into OBI stock on TipRanks’ Stock Analysis page.